Skip to main
CNTB

CNTB Stock Forecast & Price Target

CNTB Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 57%
Buy 43%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Connect Biopharma Hldgs is a strong investment due to the promising results of rademikibart in respiratory diseases, potential for expansion into chronic maintenance, and lower pricing compared to the industry average. However, the success of the company will heavily rely on the results of their upcoming clinical trials and securing sufficient funding. The company may also benefit from the FDA's flexibility in approving respiratory disease treatments and could attract more investors if their Phase 3 SEABREEZE trial is successful.

Bears say

Connect Biopharma Hldgs is developing rademikibart, a next-generation antibody for asthma and COPD with a unique mechanism of action that targets interleukin-4-receptor alpha. Despite promising preclinical data and a differentiated profile compared to existing treatments, the company's stock faces significant challenges. These include a lack of clinical data, potential dilution from future financings, and dependence on partner Simcere for success in the Chinese market. Additionally, the company's rapid onset mechanism may not be enough to differentiate the drug in the crowded respiratory market.

CNTB has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 57% of analysts recommend a Strong Buy, 43% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Connect Biopharma Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Connect Biopharma Holdings (CNTB) Forecast

Analysts have given CNTB a Strong Buy based on their latest research and market trends.

According to 7 analysts, CNTB has a Strong Buy consensus rating as of Aug 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Connect Biopharma Holdings (CNTB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.